Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053701 · ClinicalTrials.gov registry record
High-field Brain Magnetic Resonance Spectroscopy
A clinical trial of Healthy, sponsored by University of Minnesota.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT02053701: Active study of Healthy, sponsored by University of Minnesota.
NCT02053701 is a study of Healthy that is active but no longer recruiting, run by University of Minnesota. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02053701, a study of Healthy, is active but no longer recruiting, sponsored by University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Magnetic resonance spectroscopy (MRS) allows non-invasive measurement of the concentration of up to 18 metabolites in the brain ("neurochemical profile"). The objective of this proposal is to develop new methods for high-field brain MRS (3 to 7 Tesla). Our main hypothesis is that higher magnetic fields lead to improved spatial and temporal resolution and improved quantification precision. Aims 1. To obtain improved "neurochemical profiles" in the brain using single voxel proton MRS at very high field (3 Tesla to 7 Tesla). 2. To develop new methods for proton magnetic resonance spectroscopic imaging (MRSI) to obtain metabolic maps at very high field (3 Tesla to 7 Tesla). Since this project is focused on technical development, only healthy volunteers will be recruited (no patients).
Primary Outcome
This protocol is devoted exclusively to technical development and testing of MRS methods on our MR scanners. As such, there is no well-defined outcome measure or time frame. It is a continuous effort. We recruit subjects on an ongoing basis to test, optimize, and assess the performance of newly developed techniques.
Conditions Studied
Study Locations (1)
Minnesota
- Center for Magnetic Resonance Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-06-01 |
| Est. Completion | 2030-11 |
What the registry record for NCT02053701 still lists
NCT02053701 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 0 interventions.
NCT02053701 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02053701 about?
NCT02053701 is a clinical study titled "High-field Brain Magnetic Resonance Spectroscopy". Magnetic resonance spectroscopy (MRS) allows non-invasive measurement of the concentration of up to 18 metabolites in the brain ("neurochemical profile"). The objective of this proposal is to develop new methods for high-field brain MRS (3 to 7 Tesla). Our main hypothesis is that higher magnetic f...
What is the current status of trial NCT02053701?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2010-06-01. Estimated completion is 2030-11.
What conditions does trial NCT02053701 study?
This clinical trial studies the following conditions: Healthy.
Who is sponsoring clinical trial NCT02053701?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02053701 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02053701's enrollment target sits among peer trials
30 678th of 1090 higher than 363 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI